COMPANY OVERVIEW

Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network.

LIGHT (Lymphotixin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin β receptor (TNFRSF3), form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (BTLA), and CD160 (the LIGHT-signaling network). Accumulating evidence points to the dysregulation of the LIGHT-signaling network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, we believe reducing LIGHT levels can moderate immune dysregulation in many acute and chronic inflammatory disorders.

RECENT NEWS

Avalo Enters into Agreement to Divest AVTX-800 Series
Sep 12 2023, 7:00 AM EDT

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Sep 6 2023, 7:00 AM EDT

STOCK OVERVIEW

<table>
<thead>
<tr>
<th>Symbol</th>
<th>AVTX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exchange</td>
<td>Nasdaq</td>
</tr>
<tr>
<td>Market Cap</td>
<td>2.41m</td>
</tr>
<tr>
<td>Last Price</td>
<td>$0.1192</td>
</tr>
<tr>
<td>52-Week Range</td>
<td>$0.0806 - $7.00</td>
</tr>
</tbody>
</table>

09/22/2023 04:00 PM EDT

INVESTOR RELATIONS

Avalo Therapeutics
ir@avalotx.com

ICR Westwicke
Managing Director
T: 339-970-2843
chris.brinzey@westwicke.com

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.